For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
Before You Checkout
Bundle complementary compounds together — priced below buying each separately.
A dual-action GH secretagogue blend combining CJC-1295 (no DAC) and Ipamorelin for studying synergistic pulse-release dynamics.
Dosage
10mg (5mg/5mg)
Form
Lyophilized Powder
Bundle & Save
$44.95
Quantity
Research Application Guidelines
This research compound is designed exclusively for controlled in vitro studies carried out by trained professionals. It is not intended for human or animal use and must not be incorporated into foods, cosmetics, medications, or diagnostic processes.
Regulatory Notice
This material has not been evaluated by the FDA and is not sold for the purpose of diagnosing, treating, curing, or preventing any condition. All handling, storage, and research use must comply with applicable regulations and institutional requirements.
Purchase & Responsibility Agreement
By purchasing from Ascension Labs, the buyer confirms that they are a qualified researcher or authorized laboratory. All sales are final. The buyer assumes full responsibility for the proper handling, storage, usage, and regulatory compliance of this material.
What's Included
Storage Guidelines
Quality Assurance
Disclaimer: Our peptides are research-grade products for laboratory use only. They are not approved for human consumption or medical use. Always follow proper laboratory safety protocols.
This blend combines CJC-1295 (without DAC) and Ipamorelin in one vial. It is widely used in growth-hormone-axis research to study synergistic pulse-release dynamics.
Also referred to as: CJC-1295 no DAC + Ipamorelin, GHRH + GHRP blend, GH secretagogue blend.
This blend pairs two peptides in one vial: CJC-1295 without DAC (a modified GHRH(1-29) fragment, also called mod GRF 1-29) and ipamorelin (a selective GHSR-1a pentapeptide). The two act on complementary receptors within the growth-hormone axis, and the vial is characterized in research by this defined GHRH-analog plus secretagogue pairing.
The pairing combines two mechanisms: CJC-1295 activates the GHRH receptor, while ipamorelin activates the ghrelin receptor (GHSR-1a). In growth-hormone-axis research models, engaging both pathways together is studied for synergistic pulse-release dynamics that neither peptide produces alone. Cell and animal assays characterize this complementary receptor activation in vitro.
This blend uses CJC-1295 without the Drug Affinity Complex, meaning it lacks albumin binding and therefore acts over a much shorter window than the DAC variant. This shorter duration is intentional, producing a pulse-like GHRH-receptor stimulation that pairs with ipamorelin's secretagogue action in research models focused on pulsatile signaling.
Yes. Every batch of CJC-1295 wo DAC + Ipamorelin is independently tested by HPLC and mass spectrometry, and ships with a lot-specific Certificate of Analysis verifying 99.3% purity and molecular identity.
Store lyophilized CJC-1295 wo DAC + Ipamorelin at -20°C for long-term storage or 2-8°C short-term. After reconstitution, keep refrigerated at 2-8°C and avoid repeated freeze-thaw cycles.
No. CJC-1295 wo DAC + Ipamorelin is sold strictly for in-vitro research and laboratory use only. It is not a drug or supplement and is not intended for human or animal consumption.